Experts suggest membrane-based technologies could become a vital component in end-to-end intensified bioprocesses for monoclonal antibodies.
List view / Grid view
Researchers have shown that a hybrid purifier can remove host cell proteins during the downstream processing of monoclonal antibodies.
A new report has found that if COVID-19 biologics are approved, it could apply pressure to the global biomanufacturing capacity.
Christoph Krähenbühl outlines five considerations for virtual pharmaceutical companies when launching a new drug product.
Downstream processing is an integral part of the production process of biopharmaceuticals and contributes quite significantly to the overall productivity and product quality, as well as to processing costs. Melanie Diefenbacher of Genedata provides a comprehensive overview of downstream processes, highlighting several challenges and the importance of investing into automation…
Researchers have used CRISPR-Cas to edit the genes of contaminating proteins in mammalian cells used to produce recombinant-protein drugs, which could reduce costs and strengthen quality.
There are many challenges faced by the biopharmaceutical industry in order to develop and provide sufficient drugs to treat a growing and ageing population. This article discusses whether continuous processing provides the solution.
Included in this in-depth focus are articles examining the importance of child-resistant medicinal packaging and analysing whether continuous processing is the future for pharma.
Enhancing the production of pharmaceutical tablets is extremely important in modern manufacturing processes and companies will go to great lengths to ensure production runs efficiently in order to stay competitive. As time and capital implications become drivers within the production of solid dosage forms, investigation into improving production methods is…
Scientists have divised a way to manufacture protein drugs using lettuce leaves, which has presented a potential drug for pulmonary arterial hypertension.
A collaboration between the NIBRT and Avantor aims to address issues faced in downstream bioprocessing during buffer preparation for mAbs.
Research has predicted that the global single-use bioprocessing market will exhibit a CAGR of 13.6 percent over the forecast period until 2025.